Free Trial

PTC Therapeutics (PTCT) Financials

PTC Therapeutics logo
$47.86 +1.93 (+4.20%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$46.36 -1.50 (-3.13%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for PTC Therapeutics

Annual Income Statements for PTC Therapeutics

This table shows PTC Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
-363 -627 -559 -524 -438 -252 -128 -79 -142 -170
Consolidated Net Income / (Loss)
-363 -627 -559 -524 -438 -252 -128 -79 -142 -170
Net Income / (Loss) Continuing Operations
-363 -627 -559 -524 -438 -252 -128 -79 -142 -170
Total Pre-Tax Income
-363 -696 -587 -518 -403 -240 -128 -78 -142 -170
Total Operating Income
-303 -440 -447 -374 -432 -241 -116 -64 -132 -167
Total Gross Profit
749 938 654 506 362 295 252 190 83 37
Total Revenue
807 938 699 539 381 307 265 194 83 37
Operating Revenue
807 938 699 539 381 307 265 194 83 37
Total Cost of Revenue
57 0.00 45 32 19 12 13 4.58 0.00 0.00
Operating Cost of Revenue
57 - 45 32 19 12 13 4.58 - 0.00
Total Operating Expenses
1,052 1,377 1,102 881 794 536 368 254 215 204
Selling, General & Admin Expense
301 333 326 286 245 203 154 121 97 82
Research & Development Expense
534 667 651 541 478 257 172 117 118 122
Amortization Expense
61 223 117 55 37 28 23 15 0.00 0.00
Other Operating Expenses / (Income)
-4.48 -128 -26 -0.50 34 48 19 0.00 0.00 -
Impairment Charge
160 218 33 0.00 0.00 - - - - -
Total Other Income / (Expense), net
-61 -257 -140 -144 29 1.23 -12 -13 -9.48 -2.83
Interest Expense
0.00 138 0.00 0.00 - - - - - -
Interest & Investment Income
-67 -129 -91 -86 -56 -12 -13 -12 -8.28 -2.37
Other Income / (Expense), net
6.54 10 -49 -58 85 14 0.13 -1.28 -1.21 -0.47
Income Tax Expense
0.18 -70 -28 5.56 35 12 -0.03 1.34 0.57 0.49
Basic Earnings per Share
($4.73) ($8.37) ($7.79) ($7.43) ($6.64) ($4.27) ($2.75) ($2.02) ($4.17) ($5.07)
Weighted Average Basic Shares Outstanding
76.85M 74.84M 71.73M 70.47M 66.03M 58.86M 46.58M 39.18M 34.04M 33.63M
Diluted Earnings per Share
($4.73) ($8.37) ($7.79) ($7.43) ($6.64) ($4.27) ($2.75) ($2.02) ($4.17) ($5.07)
Weighted Average Diluted Shares Outstanding
76.85M 74.84M 71.73M 70.47M 66.03M 58.86M 46.58M 39.18M 34.04M 33.63M
Weighted Average Basic & Diluted Shares Outstanding
78.87M 76.61M 73.82M 71.36M 66.03M 58.86M 46.58M 39.18M 34.04M 33.63M

Quarterly Income Statements for PTC Therapeutics

This table shows PTC Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
867 -66 -107 -99 -92 -156 -133 -199 -139 -171 -109
Consolidated Net Income / (Loss)
867 -66 -107 -99 -92 -156 -133 -199 -139 -171 -109
Net Income / (Loss) Continuing Operations
867 -66 -107 -99 -92 -156 -133 -199 -139 -171 -109
Total Pre-Tax Income
930 -95 -98 -86 -85 -157 -167 -237 -135 -190 -127
Total Operating Income
970 -162 -55 -40 -45 5.82 -118 -210 -118 -200 -68
Total Gross Profit
1,163 156 197 187 210 343 187 201 206 143 217
Total Revenue
1,176 213 197 187 210 307 197 214 220 167 217
Operating Revenue
1,176 213 197 187 210 307 197 214 220 167 217
Total Cost of Revenue
13 57 0.00 0.00 0.00 -36 9.49 13 14 25 0.00
Operating Cost of Revenue
13 - - - - - 9.49 13 14 - -
Total Operating Expenses
193 318 251 227 256 338 305 411 324 343 285
Selling, General & Admin Expense
81 85 73 70 73 76 81 88 87 93 80
Research & Development Expense
109 125 161 132 116 121 164 186 195 189 165
Amortization Expense
3.80 3.31 3.04 2.87 52 77 59 47 39 36 31
Other Operating Expenses / (Income)
-0.80 -10 0.70 5.10 -0.10 -2.70 1.50 -129 2.40 6.30 -5.30
Impairment Charge
0.08 - 1.84 1.76 - - 0.00 218 - - 0.00
Total Other Income / (Expense), net
-40 68 -43 -46 -39 -163 -48 -28 -17 11 -59
Interest Expense
0.00 - 0.00 0.00 0.00 138 0.00 0.00 0.00 - -
Interest & Investment Income
-34 59 -42 -43 -41 -44 -28 -29 -27 -25 -21
Other Income / (Expense), net
-6.31 8.85 -1.87 -2.03 1.59 19 -20 1.48 9.96 35 -38
Income Tax Expense
63 -29 8.66 13 6.88 -1.26 -34 -39 3.97 -19 -18
Basic Earnings per Share
$11.09 ($0.85) ($1.39) ($1.29) ($1.20) ($2.07) ($1.76) ($2.66) ($1.88) ($2.35) ($1.53)
Weighted Average Basic Shares Outstanding
78.12M 76.85M 76.93M 76.73M 76.50M 74.84M 75.38M 74.73M 73.73M 71.73M 71.65M
Diluted Earnings per Share
$10.04 ($0.85) ($1.39) ($1.29) ($1.20) ($2.07) ($1.76) ($2.66) ($1.88) ($2.35) ($1.53)
Weighted Average Diluted Shares Outstanding
86.39M 76.85M 76.93M 76.73M 76.50M 74.84M 75.38M 74.73M 73.73M 71.73M 71.65M
Weighted Average Basic & Diluted Shares Outstanding
79.26M 78.87M 77.13M 76.92M 76.70M 76.61M 75.46M 75.34M 74.19M 73.82M 71.88M

Annual Cash Flow Statements for PTC Therapeutics

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
185 314 99 -19 -79 126 58 53 0.30 8.27
Net Cash From Operating Activities
-108 -158 -357 -251 -194 -99 -28 -10 -104 -124
Net Cash From Continuing Operating Activities
-108 -158 -357 -251 -194 -99 -28 -10 -104 -124
Net Income / (Loss) Continuing Operations
-363 -627 -559 -524 -438 -252 -128 -79 -142 -170
Consolidated Net Income / (Loss)
-363 -627 -559 -524 -438 -252 -128 -79 -142 -170
Depreciation Expense
76 237 129 64 43 32 26 18 3.29 2.88
Amortization Expense
-11 -0.33 3.61 7.15 43 -1.23 0.09 0.97 2.19 2.59
Non-Cash Adjustments To Reconcile Net Income
151 411 225 225 92 44 41 37 42 36
Changes in Operating Assets and Liabilities, net
40 -179 -155 -24 66 78 34 13 -9.16 4.70
Net Cash From Investing Activities
44 -177 290 219 -562 -387 -43 13 104 -21
Net Cash From Continuing Investing Activities
44 -177 290 219 -562 -387 -43 13 104 -21
Purchase of Property, Plant & Equipment
-6.50 -28 -32 -28 -18 -14 -7.10 -3.10 -1.78 -2.72
Acquisitions
-68 -92 -120 -57 -38 -36 -57 -77 0.00 0.00
Purchase of Investments
-667 -212 -76 -543 -1,440 -494 -69 -81 -85 -224
Sale of Property, Plant & Equipment
28 0.00 0.00 - - - - - - -
Sale and/or Maturity of Investments
598 156 518 848 944 156 90 175 192 206
Other Investing Activities, net
160 0.00 0.00 - -10 0.00 - - - -
Net Cash From Financing Activities
256 646 168 21 669 613 132 44 0.97 154
Net Cash From Continuing Financing Activities
256 646 168 21 669 613 132 44 0.97 154
Repayment of Debt
0.00 -382 -161 0.00 -29 -12 0.00 -0.43 0.00 -
Issuance of Debt
0.00 0.00 300 0.00 0.00 279 0.00 40 0.00 150
Issuance of Common Equity
5.20 5.95 56 5.79 33 327 121 2.47 0.00 0.00
Other Financing Activities, net
251 1,023 -27 15 664 18 11 2.18 0.97 4.06
Effect of Exchange Rate Changes
-7.33 3.11 -2.77 -7.82 7.69 -1.30 -3.61 6.20 -1.58 -0.64
Cash Interest Paid
5.82 36 18 9.59 9.80 7.69 7.77 6.27 4.51 0.00
Cash Income Taxes Paid
18 14 4.92 7.71 26 2.11 1.58 1.10 0.94 0.11

Quarterly Cash Flow Statements for PTC Therapeutics

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
701 256 -129 104 -46 429 -43 -9.10 -62 175 -54
Net Cash From Operating Activities
870 -30 -77 -71 71 -100 -15 -14 -29 -166 -38
Net Cash From Continuing Operating Activities
870 -30 -77 -71 71 -100 -15 -14 -29 -166 -38
Net Income / (Loss) Continuing Operations
867 -66 -107 -99 -92 -156 -133 -199 -139 -171 -109
Consolidated Net Income / (Loss)
867 -66 -107 -99 -92 -156 -133 -199 -139 -171 -109
Depreciation Expense
7.22 6.76 6.49 7.02 55 81 62 51 43 39 34
Amortization Expense
-2.01 -2.28 -2.65 -3.00 -3.40 -1.81 0.57 0.56 0.35 0.51 0.63
Non-Cash Adjustments To Reconcile Net Income
41 61 15 30 45 58 47 281 25 24 78
Changes in Operating Assets and Liabilities, net
-43 -30 11 -6.08 65 -81 9.00 -147 41 -59 -42
Net Cash From Investing Activities
-184 268 -43 -66 -115 -94 -30 -24 -29 32 136
Net Cash From Continuing Investing Activities
-184 268 -43 -66 -115 -94 -30 -24 -29 32 136
Purchase of Property, Plant & Equipment
-1.72 -3.77 -0.52 7.38 -9.59 -5.57 -6.36 -6.25 -10 -8.62 -5.38
Acquisitions
-0.81 -2.73 -10 - -55 -23 -23 -13 -33 -18 -21
Purchase of Investments
-328 -141 -217 -196 -113 -186 -8.22 -18 0.00 -12 -23
Sale of Property, Plant & Equipment
0.07 - 0.02 - - - - - - - -
Sale and/or Maturity of Investments
146 265 175 94 63 120 7.83 14 15 72 185
Net Cash From Financing Activities
9.41 26 -18 246 0.54 620 3.36 18 4.09 303 -140
Net Cash From Continuing Financing Activities
9.41 26 -18 246 0.54 620 3.36 18 4.09 303 -140
Other Financing Activities, net
9.41 23 -18 245 0.54 1,000 3.45 15 4.28 -39 10
Effect of Exchange Rate Changes
5.39 -8.65 8.54 -5.19 -2.03 3.10 -2.33 10 -7.96 6.02 -12
Cash Interest Paid
2.16 - 2.16 - 3.67 2.11 12 9.35 13 5.78 4.41
Cash Income Taxes Paid
3.04 4.77 6.66 4.08 2.04 0.52 4.44 6.98 2.22 0.89 1.08

Annual Balance Sheets for PTC Therapeutics

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
1,705 1,896 1,706 1,938 2,208 1,624 1,119 392 269 365
Total Current Assets
1,366 1,219 694 954 1,232 779 321 249 261 356
Cash & Equivalents
780 594 280 190 209 288 - 112 58 58
Short-Term Investments
360 283 131 584 895 399 58 79 173 281
Accounts Receivable
159 161 156 110 70 56 68 40 25 11
Inventories, net
23 31 22 16 19 19 16 11 0.00 -
Prepaid Expenses
44 150 106 55 39 18 9.25 6.67 4.69 5.93
Plant, Property, & Equipment, net
61 87 73 53 34 22 13 8.38 7.43 8.97
Total Noncurrent Assets
279 590 939 931 943 823 786 134 0.63 0.36
Goodwill
82 82 82 82 82 82 82 0.00 - -
Intangible Assets
119 379 706 725 715 711 701 133 0.00 -
Other Noncurrent Operating Assets
77 128 151 124 145 30 2.30 1.22 0.63 0.36
Total Liabilities & Shareholders' Equity
1,705 1,896 1,706 1,938 2,208 1,624 1,119 392 269 365
Total Liabilities
2,803 2,714 2,053 1,937 1,726 1,029 768 235 150 139
Total Current Liabilities
581 603 406 509 277 236 167 82 50 45
Accounts Payable
304 392 320 289 242 159 128 76 49 45
Current Deferred Revenue
5.51 0.80 1.35 0.00 4.15 8.24 3.72 3.94 0.00 0.14
Other Current Liabilities
271 210 85 71 31 48 23 1.67 0.87 0.00
Total Noncurrent Liabilities
2,222 2,111 1,646 1,427 1,449 794 602 153 100 94
Long-Term Debt
285 284 572 282 309 294 141 145 98 92
Noncurrent Deferred & Payable Income Tax Liabilities
0.00 56 103 137 137 131 122 0.00 - -
Other Noncurrent Operating Liabilities
1,937 1,771 972 1,008 1,003 365 329 0.24 0.34 2.05
Total Equity & Noncontrolling Interests
-1,098 -819 -347 1.44 482 594 351 156 120 226
Total Preferred & Common Equity
-1,098 -819 -347 1.44 482 594 351 156 120 226
Total Common Equity
-1,098 -819 -347 1.44 482 594 351 156 120 226
Common Stock
2,575 2,466 2,305 2,124 2,172 1,795 1,288 967 856 820
Retained Earnings
-3,647 -3,284 -2,657 -2,098 -1,629 -1,190 -939 -814 -735 -593
Accumulated Other Comprehensive Income / (Loss)
-26 -1.29 4.80 -24 -61 -11 1.46 3.97 -1.49 -1.20

Quarterly Balance Sheets for PTC Therapeutics

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
2,655 1,842 1,916 1,790 1,260 1,338 1,609 1,576
Total Current Assets
2,316 1,282 1,358 1,169 540 590 613 517
Cash & Equivalents
1,480 526 655 548 165 208 167 104
Short-Term Investments
547 487 439 336 130 130 119 184
Accounts Receivable
210 200 187 198 166 178 202 124
Inventories, net
22 36 32 30 36 32 27 15
Prepaid Expenses
57 33 46 56 44 42 99 90
Plant, Property, & Equipment, net
59 63 66 93 85 82 79 67
Total Noncurrent Assets
280 498 492 528 634 666 916 992
Goodwill
82 82 82 82 82 82 82 82
Intangible Assets
118 330 330 330 423 452 686 750
Other Noncurrent Operating Assets
79 85 80 116 129 132 147 160
Total Liabilities & Shareholders' Equity
2,655 1,842 1,916 1,790 1,260 1,338 1,609 1,576
Total Liabilities
2,841 2,897 2,897 2,684 1,931 1,917 2,066 1,803
Total Current Liabilities
595 611 610 575 492 476 442 420
Accounts Payable
318 336 339 331 371 359 332 329
Current Deferred Revenue
13 0.00 0.00 0.00 1.22 0.00 0.21 -
Other Current Liabilities
265 274 271 244 120 118 109 91
Total Noncurrent Liabilities
2,246 2,286 2,287 2,109 1,439 1,441 1,625 1,383
Long-Term Debt
286 285 285 285 573 573 572 283
Other Noncurrent Operating Liabilities
1,960 1,945 1,946 1,769 813 816 950 963
Total Equity & Noncontrolling Interests
-186 -1,054 -980 -894 -671 -579 -458 -227
Total Preferred & Common Equity
-186 -1,054 -980 -894 -671 -579 -458 -227
Total Common Equity
-186 -1,054 -980 -894 -671 -579 -458 -227
Common Stock
2,609 2,531 2,511 2,487 2,447 2,417 2,340 2,223
Retained Earnings
-2,780 -3,581 -3,474 -3,375 -3,128 -2,995 -2,796 -2,486
Accumulated Other Comprehensive Income / (Loss)
-14 -4.34 -16 -5.56 9.61 -1.43 -1.59 36

Annual Metrics And Ratios for PTC Therapeutics

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
-13.97% 34.20% 29.75% 41.45% 24.04% 15.96% 36.19% 135.04% 124.95% 45.64%
EBITDA Growth
-19.98% 46.97% -0.87% -38.71% -32.47% -119.83% -90.49% 63.28% 21.18% -69.27%
EBIT Growth
31.06% 13.54% -14.87% -24.74% -52.39% -96.82% -76.23% 50.80% 20.48% -68.22%
NOPAT Growth
31.16% 1.77% -19.49% 13.28% -79.04% -108.46% -79.94% 51.32% 20.98% -68.12%
Net Income Growth
42.02% -12.09% -6.70% -19.57% -74.17% -96.42% -62.13% 44.41% 16.63% -81.80%
EPS Growth
43.49% -7.45% -4.85% -11.90% -55.50% -55.27% -36.14% 51.56% 17.75% -70.71%
Operating Cash Flow Growth
32.02% 55.58% -41.91% -29.51% -96.75% -256.86% -174.68% 90.28% 16.71% -117.09%
Free Cash Flow Firm Growth
-64.08% 296.18% -99.73% -200.96% 302.93% 53.73% -46.11% -69.63% 11.57% -92.00%
Invested Capital Growth
-38.36% -658.36% 45.35% -8.95% -241.01% -19.75% 150.68% 894.42% 34.20% -25.65%
Revenue Q/Q Growth
-10.42% 17.50% 0.31% -11.80% 58.68% 26.19% -14.61% 37.33% 17.73% 0.21%
EBITDA Q/Q Growth
-1,201.73% 54.31% -9.06% -164.54% 41.09% -10.65% -102.86% 42.58% 15.25% -10.44%
EBIT Q/Q Growth
-151.50% 30.67% -10.97% -115.24% 33.80% -10.21% -66.22% 31.28% 15.18% -10.87%
NOPAT Q/Q Growth
-125.19% 31.93% -34.84% -60.50% 23.03% -15.98% -63.68% 32.14% 14.95% -10.57%
Net Income Q/Q Growth
19.84% 2.35% -5.20% -73.36% 26.27% -16.12% -52.36% 26.21% 14.53% -16.13%
EPS Q/Q Growth
20.50% 3.24% -4.28% -15.73% 2.21% -3.64% -67.68% 30.10% 14.90% -21.88%
Operating Cash Flow Q/Q Growth
39.49% 29.31% -37.42% -1.81% -38.71% 4.77% -414.46% 77.47% 14.11% -21.90%
Free Cash Flow Firm Q/Q Growth
-74.58% 414.05% -40.97% -47.86% 14.51% 9.34% -13.59% 14.45% 6.22% -7.60%
Invested Capital Q/Q Growth
-9.52% -259.56% 20.00% -2.54% 4.45% -17.34% -3.98% -7.94% -19.52% -129.79%
Profitability Metrics
- - - - - - - - - -
Gross Margin
92.89% 100.00% 93.61% 94.00% 95.03% 96.05% 95.21% 97.65% 100.00% 100.00%
EBITDA Margin
-28.72% -20.59% -52.11% -67.03% -68.36% -64.01% -33.76% -24.14% -154.51% -440.98%
Operating Margin
-37.50% -46.86% -64.03% -69.52% -113.39% -78.56% -43.70% -33.07% -159.67% -454.58%
EBIT Margin
-36.69% -45.78% -71.07% -80.27% -91.02% -74.09% -43.65% -33.73% -161.13% -455.84%
Profit (Net Income) Margin
-45.03% -66.81% -80.00% -97.27% -115.07% -81.95% -48.38% -40.64% -171.83% -463.60%
Tax Burden Percent
100.05% 90.02% 95.15% 101.07% 108.74% 104.86% 99.98% 101.72% 100.40% 100.29%
Interest Burden Percent
122.66% 162.12% 118.30% 119.90% 116.26% 105.49% 110.86% 118.44% 106.21% 101.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -67.83% -41.92% -93.47% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% -30.82% 36.03% -55.64% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 14.58% -8.58% 36.23% 0.00% 0.00%
Return on Equity (ROE)
37.91% 107.51% 323.46% -216.75% -81.42% -53.24% -50.51% -57.24% -82.24% -65.00%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -45.92% -127.86% -153.44% 0.00% 0.00%
Operating Return on Assets (OROA)
-16.44% -23.85% -27.26% -20.85% -18.09% -16.58% -15.30% -19.84% -42.00% -47.99%
Return on Assets (ROA)
-20.18% -34.80% -30.68% -25.27% -22.87% -18.34% -16.95% -23.90% -44.79% -48.80%
Return on Common Equity (ROCE)
37.91% 107.51% 323.46% -216.75% -81.42% -53.24% -50.51% -57.24% -82.24% -65.00%
Return on Equity Simple (ROE_SIMPLE)
33.08% 76.55% 161.06% 0.00% -90.91% -42.33% -36.52% -50.50% -118.84% -75.42%
Net Operating Profit after Tax (NOPAT)
-212 -308 -313 -262 -302 -169 -81 -45 -92 -117
NOPAT Margin
-26.25% -32.80% -44.82% -48.67% -79.38% -54.99% -30.59% -23.15% -111.77% -318.20%
Net Nonoperating Expense Percent (NNEP)
-20.94% -147.83% -271.75% -46.07% -23.29% -37.01% -77.95% -37.83% -26.11% -19.01%
Return On Investment Capital (ROIC_SIMPLE)
26.06% 57.58% -139.42% - - - - - - -
Cost of Revenue to Revenue
7.11% 0.00% 6.39% 6.00% 4.97% 3.95% 4.79% 2.35% 0.00% 0.00%
SG&A Expenses to Revenue
37.30% 35.46% 46.65% 53.06% 64.39% 65.98% 58.00% 62.38% 117.44% 223.25%
R&D to Revenue
66.25% 71.08% 93.23% 100.39% 125.44% 83.87% 64.96% 60.42% 142.23% 331.33%
Operating Expenses to Revenue
130.39% 146.86% 157.63% 163.52% 208.42% 174.61% 138.91% 130.72% 259.67% 554.58%
Earnings before Interest and Taxes (EBIT)
-296 -429 -497 -432 -347 -227 -116 -66 -133 -168
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-232 -193 -364 -361 -260 -196 -89 -47 -128 -162
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 1,958.20 8.64 4.98 4.94 4.42 3.13 4.91
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.52 3.13 4.91
Price to Revenue (P/Rev)
4.32 2.22 3.93 5.23 10.94 9.64 6.54 3.56 4.53 30.20
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 11.67 6.00 5.86 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
3.26 1.59 4.16 4.59 8.85 8.43 6.26 3.32 2.91 23.48
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
7.97 1.62 0.00 0.00 14.53 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
-0.26 -0.35 -1.65 300.02 0.64 0.53 0.44 0.93 0.82 0.41
Long-Term Debt to Equity
-0.26 -0.35 -1.65 196.03 0.64 0.49 0.40 0.93 0.82 0.41
Financial Leverage
0.75 0.37 0.52 -2.35 -1.08 -0.47 -0.24 -0.65 -1.10 -1.07
Leverage Ratio
-1.88 -3.09 -10.54 8.58 3.56 2.90 2.98 2.39 1.84 1.33
Compound Leverage Factor
-2.30 -5.01 -12.47 10.28 4.14 3.06 3.30 2.84 1.95 1.35
Debt to Total Capital
-35.12% -53.19% 254.51% 99.67% 39.08% 34.56% 30.38% 48.10% 45.09% 28.90%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 34.55% 0.00% 2.20% 2.32% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
-35.12% -53.19% 254.51% 65.12% 39.08% 32.36% 28.06% 48.10% 45.09% 28.90%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
135.12% 153.19% -154.51% 0.33% 60.92% 65.44% 69.62% 51.90% 54.91% 71.10%
Debt to EBITDA
-1.23 -1.47 -1.57 -1.20 -1.19 -1.60 -1.71 -3.09 -0.77 -0.57
Net Debt to EBITDA
3.69 3.07 -0.44 0.95 3.05 1.90 0.83 0.99 1.04 1.52
Long-Term Debt to EBITDA
-1.23 -1.47 -1.57 -0.78 -1.19 -1.50 -1.58 -3.09 -0.77 -0.57
Debt to NOPAT
-1.35 -0.92 -1.83 -1.65 -1.02 -1.86 -1.89 -3.22 -1.06 -0.79
Net Debt to NOPAT
4.03 1.93 -0.51 1.30 2.63 2.21 0.92 1.03 1.44 2.11
Long-Term Debt to NOPAT
-1.35 -0.92 -1.83 -1.08 -1.02 -1.74 -1.75 -3.22 -1.06 -0.79
Altman Z-Score
-1.80 -1.83 -1.73 -0.83 0.59 0.83 0.24 -0.69 -2.70 2.12
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.35 2.02 1.71 1.87 4.44 3.30 1.92 3.04 5.27 7.84
Quick Ratio
2.23 1.72 1.39 1.74 4.23 3.15 0.76 2.82 5.17 7.71
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
329 917 -468 -234 232 -114 -247 -169 -100 -113
Operating Cash Flow to CapEx
0.00% -557.06% -1,113.99% -890.84% -1,087.66% -717.01% -389.47% -324.51% -5,831.42% -4,571.21%
Free Cash Flow to Firm to Interest Expense
0.00 6.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 -1.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 -1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.45 0.52 0.38 0.26 0.20 0.22 0.35 0.59 0.26 0.11
Accounts Receivable Turnover
5.05 5.93 5.25 5.97 6.07 4.97 4.89 5.95 4.59 4.73
Inventory Turnover
2.13 0.00 2.37 1.87 1.00 0.69 0.94 0.00 0.00 0.00
Fixed Asset Turnover
10.90 11.75 11.17 12.47 13.75 17.93 25.13 24.60 10.08 4.06
Accounts Payable Turnover
0.16 0.00 0.15 0.12 0.09 0.08 0.12 0.07 0.00 0.00
Days Sales Outstanding (DSO)
72.25 61.58 69.49 61.12 60.14 73.39 74.66 61.33 79.49 77.13
Days Inventory Outstanding (DIO)
170.97 0.00 153.85 195.06 365.94 532.42 387.05 0.00 0.00 0.00
Days Payable Outstanding (DPO)
2,213.84 0.00 2,488.25 2,997.36 3,867.78 4,323.38 2,947.73 4,992.33 0.00 0.00
Cash Conversion Cycle (CCC)
-1,970.63 61.58 -2,264.91 -2,741.18 -3,441.70 -3,717.57 -2,486.02 -4,931.01 79.49 77.13
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-1,952 -1,411 -186 -341 -313 222 276 110 -14 -21
Invested Capital Turnover
-0.48 -1.17 -2.65 -1.65 -8.38 1.23 1.37 4.04 -4.73 -1.94
Increase / (Decrease) in Invested Capital
-541 -1,225 154 -28 -534 -55 166 124 7.21 -4.30
Enterprise Value (EV)
2,627 1,487 2,905 2,474 3,370 2,587 1,657 646 241 863
Market Capitalization
3,481 2,080 2,744 2,816 4,164 2,960 1,732 692 374 1,110
Book Value per Share
($14.24) ($10.85) ($4.83) $0.02 $7.06 $9.64 $6.95 $3.77 $3.48 $6.59
Tangible Book Value per Share
($16.85) ($16.97) ($15.79) ($11.40) ($4.63) ($3.22) ($8.57) $0.57 $3.48 $6.59
Total Capital
-813 -534 225 433 791 908 504 301 218 318
Total Debt
285 284 572 431 309 314 153 145 98 92
Total Long-Term Debt
285 284 572 282 309 294 141 145 98 92
Net Debt
-854 -593 161 -342 -795 -373 -75 -46 -133 -247
Capital Expenditures (CapEx)
-22 28 32 28 18 14 7.10 3.10 1.78 2.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-355 -261 -123 -179 -149 -123 -62 -24 -20 -28
Debt-free Net Working Capital (DFNWC)
785 616 288 595 954 563 166 167 212 311
Net Working Capital (NWC)
785 616 288 445 954 543 154 167 212 311
Net Nonoperating Expense (NNE)
151 319 246 262 136 83 47 34 50 53
Net Nonoperating Obligations (NNO)
-854 -593 161 -342 -795 -373 -75 -46 -133 -247
Total Depreciation and Amortization (D&A)
64 236 132 71 86 31 26 19 5.48 5.46
Debt-free, Cash-free Net Working Capital to Revenue
-44.02% -27.85% -17.62% -33.20% -39.19% -40.11% -23.37% -12.47% -24.19% -77.14%
Debt-free Net Working Capital to Revenue
97.24% 65.63% 41.15% 110.39% 250.66% 183.54% 62.60% 85.92% 255.92% 844.70%
Net Working Capital to Revenue
97.24% 65.63% 41.15% 82.63% 250.66% 177.02% 58.19% 85.92% 255.92% 844.70%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($4.73) ($8.37) ($7.79) ($7.43) ($6.64) ($4.27) ($2.75) ($2.02) ($4.17) ($5.07)
Adjusted Weighted Average Basic Shares Outstanding
76.85M 74.84M 71.73M 70.47M 70.32M 62.63M 58.40M 41.80M 34.56M 34.27M
Adjusted Diluted Earnings per Share
($4.73) ($8.37) ($7.79) ($7.43) ($6.64) ($4.27) ($2.75) ($2.02) ($4.17) ($5.07)
Adjusted Weighted Average Diluted Shares Outstanding
76.85M 74.84M 71.73M 70.47M 70.32M 62.63M 58.40M 41.80M 34.56M 34.27M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 ($6.64) ($4.27) ($2.75) ($2.02) ($4.17) ($5.07)
Adjusted Weighted Average Basic & Diluted Shares Outstanding
78.87M 76.61M 73.82M 71.36M 66.03M 58.86M 46.58M 39.18M 34.04M 33.63M
Normalized Net Operating Profit after Tax (NOPAT)
-100 -155 -290 -262 -302 -169 -81 -45 -92 -117
Normalized NOPAT Margin
-12.34% -16.55% -41.47% -48.67% -79.38% -54.99% -30.59% -23.15% -111.77% -318.20%
Pre Tax Income Margin
-45.01% -74.23% -84.07% -96.24% -105.82% -78.16% -48.39% -39.95% -171.14% -462.28%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -3.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 -2.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 -3.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 -2.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PTC Therapeutics

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
459.73% -30.58% 0.11% -12.68% -4.66% 83.41% -9.47% 29.17% 48.17% 1.32% 56.50%
EBITDA Growth
11,817.45% -243.77% 30.68% 75.57% 112.61% 182.40% -6.44% -62.32% 8.81% -31.65% 23.61%
EBIT Growth
2,297.62% -719.58% 59.27% 79.70% 59.26% 115.00% -30.19% -64.19% -9.44% -42.28% 4.94%
NOPAT Growth
2,941.90% -2,890.19% 53.87% 80.81% 61.35% 102.91% -73.29% -126.87% -35.94% -136.45% 26.74%
Net Income Growth
1,046.28% 57.71% 19.79% 50.13% 34.10% 8.83% -21.64% -30.77% -9.65% -19.28% 18.19%
EPS Growth
936.67% 58.94% 21.02% 51.50% 36.17% 11.91% -15.03% -24.88% -5.62% -15.76% 19.05%
Operating Cash Flow Growth
1,129.64% 70.08% -430.28% -406.04% 339.94% 39.57% 61.84% 74.44% 69.72% -141.09% 25.68%
Free Cash Flow Firm Growth
3.61% -65.21% 1,652.56% 2,562.21% 921.87% 517.10% 152.41% 55.51% -96.59% -840.63% -144.55%
Invested Capital Growth
-28.98% -38.36% -354.23% -419.10% -769.88% -658.36% -68.73% -34.92% 30.31% 45.35% 29.96%
Revenue Q/Q Growth
451.71% 8.33% 5.40% -11.14% -31.57% 56.20% -8.06% -2.98% 31.64% -22.90% 31.17%
EBITDA Q/Q Growth
750.20% -183.63% -37.47% -570.07% -92.16% 236.77% 51.56% -142.71% 48.75% -76.67% 26.13%
EBIT Q/Q Growth
727.80% -172.32% -33.47% 3.69% -277.00% 117.90% 33.47% -93.26% 34.83% -55.36% 16.09%
NOPAT Q/Q Growth
895.45% -197.91% -35.54% 11.52% -880.98% 104.93% 43.61% -78.16% 41.29% -193.81% 26.17%
Net Income Q/Q Growth
1,415.24% 38.22% -7.54% -8.30% 41.22% -17.16% 33.14% -43.12% 18.68% -56.33% 28.12%
EPS Q/Q Growth
1,281.18% 38.85% -7.75% -7.50% 42.03% -17.61% 33.83% -41.49% 20.00% -53.59% 28.17%
Operating Cash Flow Q/Q Growth
2,999.96% 61.03% -7.75% -200.98% 170.56% -590.74% -2.83% 52.12% 82.23% -336.23% 31.13%
Free Cash Flow Firm Q/Q Growth
212.73% -68.37% -4.52% 9.71% 5.01% 1,493.23% 234.15% 63.38% 46.71% -100.19% -13.87%
Invested Capital Q/Q Growth
1.29% -9.52% 0.34% -19.71% -5.89% -259.56% -13.90% -100.60% 7.68% 20.00% 8.93%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
98.91% 73.07% 100.00% 100.00% 100.00% 111.84% 95.17% 94.05% 93.58% 85.12% 100.00%
EBITDA Margin
82.40% -69.92% -26.70% -20.47% 3.87% 33.76% -38.56% -73.20% -29.26% -75.16% -32.80%
Operating Margin
82.50% -76.18% -27.70% -21.54% -21.63% 1.90% -60.11% -98.01% -53.37% -119.67% -31.40%
EBIT Margin
81.96% -72.03% -28.65% -22.63% -20.87% 8.07% -70.42% -97.31% -48.85% -98.67% -48.97%
Profit (Net Income) Margin
73.68% -30.91% -54.20% -53.12% -43.58% -50.74% -67.64% -93.02% -63.05% -102.08% -50.35%
Tax Burden Percent
93.20% 69.57% 108.84% 115.68% 108.12% 99.20% 79.82% 83.75% 102.94% 90.09% 85.93%
Interest Burden Percent
96.46% 61.68% 173.80% 202.95% 193.10% -633.76% 120.34% 114.14% 125.39% 114.83% 119.64%
Effective Tax Rate
6.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-110.19% 37.91% 52.54% 61.50% 85.72% 107.51% 142.96% 162.33% 208.43% 323.46% 871.29%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
65.37% -32.28% -16.64% -12.52% -11.40% 4.20% -39.64% -50.71% -22.08% -37.85% -19.04%
Return on Assets (ROA)
58.77% -13.85% -31.47% -29.40% -23.79% -26.43% -38.07% -48.47% -28.51% -39.15% -19.57%
Return on Common Equity (ROCE)
-110.19% 37.91% 52.54% 61.50% 85.72% 107.51% 142.96% 162.33% 208.43% 323.46% 871.29%
Return on Equity Simple (ROE_SIMPLE)
-320.22% 0.00% 42.98% 48.92% 64.80% 0.00% 95.66% 106.69% 124.85% 0.00% 234.19%
Net Operating Profit after Tax (NOPAT)
904 -114 -38 -28 -32 4.07 -83 -147 -82 -140 -48
NOPAT Margin
76.88% -53.32% -19.39% -15.08% -15.14% 1.33% -42.08% -68.60% -37.36% -83.77% -21.98%
Net Nonoperating Expense Percent (NNEP)
-3.22% 6.61% -30.45% -24.76% -38.00% -74.10% 36.86% 64.64% 87.19% -33.88% -27.82%
Return On Investment Capital (ROIC_SIMPLE)
904.64% 13.99% - - - -0.76% - - - -62.43% -
Cost of Revenue to Revenue
1.09% 26.93% 0.00% 0.00% 0.00% -11.84% 4.83% 5.95% 6.42% 14.88% 0.00%
SG&A Expenses to Revenue
6.88% 39.73% 37.33% 37.22% 34.87% 24.85% 41.15% 41.37% 39.44% 55.38% 36.90%
R&D to Revenue
9.27% 58.53% 82.02% 70.79% 55.27% 39.52% 83.54% 86.94% 88.54% 112.71% 76.21%
Operating Expenses to Revenue
16.41% 149.25% 127.70% 121.54% 121.63% 109.95% 155.28% 192.05% 146.95% 204.79% 131.40%
Earnings before Interest and Taxes (EBIT)
964 -154 -56 -42 -44 25 -138 -208 -108 -165 -106
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
969 -149 -53 -38 8.13 104 -76 -156 -64 -126 -71
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
2.27 4.32 3.17 2.60 2.40 2.22 2.12 3.69 4.64 3.93 5.16
Price to Earnings (P/E)
6.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
14.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
1.28 3.26 2.36 1.71 1.76 1.59 2.46 3.97 5.01 4.16 5.15
Enterprise Value to EBITDA (EV/EBITDA)
3.12 0.00 101.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
3.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
3.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
3.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
2.10 7.97 1.64 1.18 1.53 1.62 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-1.54 -0.26 -0.27 -0.29 -0.32 -0.35 -0.85 -0.99 -1.25 -1.65 -1.25
Long-Term Debt to Equity
-1.54 -0.26 -0.27 -0.29 -0.32 -0.35 -0.85 -0.99 -1.25 -1.65 -1.25
Financial Leverage
2.17 0.75 0.26 0.37 0.23 0.37 -0.30 -0.21 -0.24 0.52 3.63
Leverage Ratio
-4.12 -1.88 -1.80 -2.09 -2.51 -3.09 -3.16 -4.13 -6.22 -10.54 -29.38
Compound Leverage Factor
-3.97 -1.16 -3.13 -4.24 -4.86 19.58 -3.80 -4.71 -7.80 -12.11 -35.15
Debt to Total Capital
285.85% -35.12% -37.06% -40.96% -46.69% -53.19% -587.05% -8,643.67% 499.51% 254.51% 506.31%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
285.85% -35.12% -37.06% -40.96% -46.69% -53.19% -587.05% -8,643.67% 499.51% 254.51% 506.31%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-185.85% 135.12% 137.06% 140.96% 146.69% 153.19% 687.05% 8,743.67% -399.51% -154.51% -406.31%
Debt to EBITDA
0.39 -1.23 13.56 -128.12 -2.36 -1.47 -1.36 -1.37 -1.60 -1.57 -0.85
Net Debt to EBITDA
-2.39 3.69 -34.63 363.69 4.98 3.07 -0.66 -0.56 -0.80 -0.44 0.02
Long-Term Debt to EBITDA
0.39 -1.23 13.56 -128.12 -2.36 -1.47 -1.36 -1.37 -1.60 -1.57 -0.85
Debt to NOPAT
0.44 -1.35 -3.03 -2.05 -1.11 -0.92 -1.27 -1.37 -1.71 -1.83 -1.22
Net Debt to NOPAT
-2.67 4.03 7.74 5.83 2.33 1.93 -0.62 -0.56 -0.85 -0.51 0.02
Long-Term Debt to NOPAT
0.44 -1.35 -3.03 -2.05 -1.11 -0.92 -1.27 -1.37 -1.71 -1.83 -1.22
Altman Z-Score
2.03 -1.52 -1.31 -1.19 -1.31 -1.04 -2.63 -1.99 -1.01 -1.09 -0.72
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.89 2.35 2.10 2.23 2.03 2.02 1.10 1.24 1.39 1.71 1.23
Quick Ratio
3.76 2.23 1.99 2.10 1.88 1.72 0.94 1.08 1.11 1.39 0.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1,337 428 1,352 1,416 1,291 1,229 77 -58 -157 -295 -147
Operating Cash Flow to CapEx
52,605.99% -796.50% -15,276.19% 0.00% 738.02% -1,801.80% -228.39% -226.10% -287.16% -1,924.88% -706.89%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 8.94 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -0.73 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -0.77 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.80 0.45 0.58 0.55 0.55 0.52 0.56 0.52 0.45 0.38 0.39
Accounts Receivable Turnover
8.69 5.05 4.93 4.94 4.64 5.93 5.50 5.22 4.49 5.25 6.30
Inventory Turnover
2.15 2.13 0.82 1.21 1.81 0.00 2.42 2.20 2.32 2.37 2.40
Fixed Asset Turnover
23.29 10.90 12.15 12.16 10.77 11.75 10.51 11.14 11.12 11.17 12.30
Accounts Payable Turnover
0.17 0.16 0.08 0.11 0.15 0.00 0.18 0.15 0.17 0.15 0.13
Days Sales Outstanding (DSO)
42.02 72.25 74.10 73.91 78.61 61.58 66.35 69.87 81.28 69.49 57.92
Days Inventory Outstanding (DIO)
170.05 170.97 447.65 301.77 201.57 0.00 150.61 165.73 157.17 153.85 152.30
Days Payable Outstanding (DPO)
2,132.45 2,213.84 4,431.68 3,296.17 2,356.75 0.00 2,085.12 2,430.14 2,168.89 2,488.25 2,911.53
Cash Conversion Cycle (CCC)
-1,920.38 -1,970.63 -3,909.93 -2,920.50 -2,076.57 61.58 -1,868.17 -2,194.54 -1,930.43 -2,264.91 -2,701.31
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1,927 -1,952 -1,783 -1,789 -1,494 -1,411 -392 -345 -172 -186 -233
Invested Capital Turnover
-1.04 -0.48 -0.83 -0.84 -1.11 -1.17 -2.55 -2.73 -3.68 -2.65 -2.47
Increase / (Decrease) in Invested Capital
-433 -541 -1,390 -1,444 -1,322 -1,225 -160 -89 75 154 99
Enterprise Value (EV)
2,278 2,627 2,126 1,537 1,628 1,487 1,967 3,252 3,861 2,905 3,586
Market Capitalization
4,019 3,481 2,854 2,345 2,229 2,080 1,688 3,017 3,576 2,744 3,591
Book Value per Share
($2.36) ($14.24) ($13.71) ($12.78) ($11.67) ($10.85) ($8.90) ($7.81) ($6.21) ($4.83) ($3.17)
Tangible Book Value per Share
($4.90) ($16.85) ($19.07) ($18.15) ($17.05) ($16.97) ($15.61) ($15.01) ($16.63) ($15.79) ($14.80)
Total Capital
100 -813 -769 -695 -609 -534 -98 -6.63 115 225 56
Total Debt
286 285 285 285 285 284 573 573 572 572 283
Total Long-Term Debt
286 285 285 285 285 284 573 573 572 572 283
Net Debt
-1,741 -854 -728 -808 -600 -593 278 235 286 161 -5.68
Capital Expenditures (CapEx)
1.65 3.77 0.50 -7.38 9.59 5.57 6.36 6.25 10 8.62 5.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-306 -355 -343 -345 -291 -261 -247 -225 -115 -123 -191
Debt-free Net Working Capital (DFNWC)
1,721 785 671 748 594 616 48 113 172 288 97
Net Working Capital (NWC)
1,721 785 671 748 594 616 48 113 172 288 97
Net Nonoperating Expense (NNE)
38 -48 68 71 60 160 50 52 57 31 62
Net Nonoperating Obligations (NNO)
-1,741 -854 -728 -808 -600 -593 278 235 286 161 -5.68
Total Depreciation and Amortization (D&A)
5.21 4.49 3.83 4.02 52 79 63 52 43 39 35
Debt-free, Cash-free Net Working Capital to Revenue
-17.27% -44.02% -38.03% -38.33% -31.33% -27.85% -30.89% -27.43% -14.87% -17.62% -27.45%
Debt-free Net Working Capital to Revenue
97.08% 97.24% 74.48% 83.08% 64.06% 65.63% 6.04% 13.84% 22.29% 41.15% 13.95%
Net Working Capital to Revenue
97.08% 97.24% 74.48% 83.08% 64.06% 65.63% 6.04% 13.84% 22.29% 41.15% 13.95%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$11.09 ($0.85) ($1.39) ($1.29) ($1.20) ($2.07) ($1.76) ($2.66) ($1.88) ($2.35) ($1.53)
Adjusted Weighted Average Basic Shares Outstanding
78.12M 76.85M 76.93M 76.73M 76.50M 74.84M 75.38M 74.73M 73.73M 71.73M 71.65M
Adjusted Diluted Earnings per Share
$10.04 ($0.85) ($1.39) ($1.29) ($1.20) ($2.07) ($1.76) ($2.66) ($1.88) ($2.35) ($1.53)
Adjusted Weighted Average Diluted Shares Outstanding
86.39M 76.85M 76.93M 76.73M 76.50M 74.84M 75.38M 74.73M 73.73M 71.73M 71.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
79.26M 78.87M 77.13M 76.92M 76.70M 76.61M 75.46M 75.34M 74.19M 73.82M 71.88M
Normalized Net Operating Profit after Tax (NOPAT)
904 -114 -37 -27 -32 4.07 -83 5.78 -82 -140 -48
Normalized NOPAT Margin
76.89% -53.32% -18.73% -14.42% -15.14% 1.33% -42.08% 2.70% -37.36% -83.77% -21.98%
Pre Tax Income Margin
79.06% -44.42% -49.80% -45.92% -40.31% -51.15% -84.75% -111.07% -61.25% -113.31% -58.59%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.14 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About PTC Therapeutics' Financials

When does PTC Therapeutics's fiscal year end?

According to the most recent income statement we have on file, PTC Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has PTC Therapeutics' net income changed over the last 9 years?

PTC Therapeutics' net income appears to be on an upward trend, with a most recent value of -$363.30 million in 2024, rising from -$170.45 million in 2015. The previous period was -$626.60 million in 2023. View PTC Therapeutics' forecast to see where analysts expect PTC Therapeutics to go next.

What is PTC Therapeutics's operating income?
PTC Therapeutics's total operating income in 2024 was -$302.57 million, based on the following breakdown:
  • Total Gross Profit: $749.38 million
  • Total Operating Expenses: $1.05 billion
How has PTC Therapeutics revenue changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' total revenue changed from $36.77 million in 2015 to $806.78 million in 2024, a change of 2,094.4%.

How much debt does PTC Therapeutics have?

PTC Therapeutics' total liabilities were at $2.80 billion at the end of 2024, a 3.3% increase from 2023, and a 1,912.6% increase since 2015.

How much cash does PTC Therapeutics have?

In the past 9 years, PTC Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $779.71 million in 2024, and is currently $779.71 million as of their latest financial filing in 2024.

How has PTC Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, PTC Therapeutics' book value per share changed from 6.59 in 2015 to -14.24 in 2024, a change of -315.9%.



This page (NASDAQ:PTCT) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners